RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Bernard Arulanandam to Lung

This is a "connection" page, showing publications Bernard Arulanandam has written about Lung.
Connection Strength

2.472
  1. Keck J, Chambers JP, Kancharla A, Bashir DH, Henley L, Schenkel K, Castillo K, Neal Guentzel M, Gupta R, Arulanandam BP. The Role of MicroRNA-155 in Chlamydia muridarum Infected lungs. Microbes Infect. 2020 09; 22(8):360-365.
    View in: PubMed
    Score: 0.574
  2. Jupelli M, Selby DM, Guentzel MN, Chambers JP, Forsthuber TG, Zhong G, Murthy AK, Arulanandam BP. The contribution of interleukin-12/interferon-gamma axis in protection against neonatal pulmonary Chlamydia muridarum challenge. J Interferon Cytokine Res. 2010 Jun; 30(6):407-15.
    View in: PubMed
    Score: 0.293
  3. Ray HJ, Chu P, Wu TH, Lyons CR, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The Fischer 344 rat reflects human susceptibility to francisella pulmonary challenge and provides a new platform for virulence and protection studies. PLoS One. 2010 Apr 01; 5(4):e9952.
    View in: PubMed
    Score: 0.289
  4. Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.
    View in: PubMed
    Score: 0.253
  5. Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother. 2004 Dec; 48(12):4513-9.
    View in: PubMed
    Score: 0.200
  6. Murthy AK, Sharma J, Coalson JJ, Zhong G, Arulanandam BP. Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. Cell Immunol. 2004 Jul; 230(1):56-64.
    View in: PubMed
    Score: 0.194
  7. Shrihari S, May HC, Yu JJ, Papp SB, Chambers JP, Guentzel MN, Arulanandam BP. Thioredoxin-mediated alteration of protein content and cytotoxicity of Acinetobacter baumannii outer membrane vesicles. Exp Biol Med (Maywood). 2022 02; 247(3):282-288.
    View in: PubMed
    Score: 0.161
  8. Lanka GK, Yu JJ, Gong S, Gupta R, Mustafa SB, Murthy AK, Zhong G, Chambers JP, Guentzel MN, Arulanandam BP. IgA modulates respiratory dysfunction as a sequela to pulmonary chlamydial infection as neonates. Pathog Dis. 2016 Apr; 74(3).
    View in: PubMed
    Score: 0.108
  9. Chambers JP, Yu JJ, Jupelli M, Weintraub ST, Lopez-Ribot JL, Valdes JJ, Arulanandam BP. Alpha-1 antitrypsin is markedly decreased following pulmonary F. tularensis challenge. Front Cell Infect Microbiol. 2011; 1:20.
    View in: PubMed
    Score: 0.082
  10. Jupelli M, Murthy AK, Chaganty BK, Guentzel MN, Selby DM, Vasquez MM, Mustafa SB, Henson BM, Seidner SR, Zhong G, Arulanandam BP. Neonatal chlamydial pneumonia induces altered respiratory structure and function lasting into adult life. Lab Invest. 2011 Oct; 91(10):1530-9.
    View in: PubMed
    Score: 0.079
  11. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 2009 Apr; 16(4):444-52.
    View in: PubMed
    Score: 0.067
  12. Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, Forsthuber TG, Guentzel MN, Klose KE, Berton MT, Arulanandam BP. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9313-8.
    View in: PubMed
    Score: 0.064
  13. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun. 2001 Nov; 69(11):6718-24.
    View in: PubMed
    Score: 0.040
  14. Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999 Oct; 180(4):940-9.
    View in: PubMed
    Score: 0.035
  15. Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine. 1999 Jan 21; 17(3):252-60.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support